These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 12955470

  • 1. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY, Jolivet J, Leblond L, Hamelin B, Ouellet F, Barbeau S, Richard A, Gourdeau H.
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [Abstract] [Full Text] [Related]

  • 3. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
    Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, Bowlin T.
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
    [Abstract] [Full Text] [Related]

  • 4. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Gourdeau H, Leblond L, Hamelin B, Dong K, Ouellet F, Boudreau C, Custeau D, Richard A, Gilbert MJ, Jolivet J.
    Clin Cancer Res; 2004 Nov 15; 10(22):7692-702. PubMed ID: 15570003
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, Lafrenière RG, Cass CE.
    Cancer Res; 2001 Oct 01; 61(19):7217-24. PubMed ID: 11585758
    [Abstract] [Full Text] [Related]

  • 6. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
    Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L, Cass CE, Grey M, Gourdeau H.
    BMC Cancer; 2007 Jul 03; 7():121. PubMed ID: 17608948
    [Abstract] [Full Text] [Related]

  • 7. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohammad RM, Ravindranath Y, Matherly LH.
    Cancer Res; 2000 Nov 15; 60(22):6421-6. PubMed ID: 11103808
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM, Li B, Rimmer E, VanRoey M, Jooss K.
    Exp Hematol; 2008 Mar 15; 36(3):319-28. PubMed ID: 18279719
    [Abstract] [Full Text] [Related]

  • 9. Troxacitabine-based therapy of refractory leukemia.
    Giles FJ.
    Expert Rev Anticancer Ther; 2002 Jun 15; 2(3):261-6. PubMed ID: 12113049
    [Abstract] [Full Text] [Related]

  • 10. Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine.
    Someya H, Waud WR, Parker WB.
    Cancer Chemother Pharmacol; 2006 Jun 15; 57(6):772-80. PubMed ID: 16180016
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
    Parker WB, Shaddix SC, Gilbert KS, Shepherd RV, Waud WR.
    Cancer Chemother Pharmacol; 2009 Jul 15; 64(2):253-61. PubMed ID: 19002461
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.
    Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P.
    Cancer Res; 2008 Apr 01; 68(7):2349-57. PubMed ID: 18381442
    [Abstract] [Full Text] [Related]

  • 20. The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine.
    Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE.
    Mol Pharmacol; 2006 Jul 01; 70(1):303-10. PubMed ID: 16617163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.